JP2023527542A5 - - Google Patents
Info
- Publication number
- JP2023527542A5 JP2023527542A5 JP2022573247A JP2022573247A JP2023527542A5 JP 2023527542 A5 JP2023527542 A5 JP 2023527542A5 JP 2022573247 A JP2022573247 A JP 2022573247A JP 2022573247 A JP2022573247 A JP 2022573247A JP 2023527542 A5 JP2023527542 A5 JP 2023527542A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032451P | 2020-05-29 | 2020-05-29 | |
| US63/032,451 | 2020-05-29 | ||
| PCT/US2021/034489 WO2021243002A1 (en) | 2020-05-29 | 2021-05-27 | Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023527542A JP2023527542A (ja) | 2023-06-29 |
| JPWO2021243002A5 JPWO2021243002A5 (https=) | 2024-06-03 |
| JP2023527542A5 true JP2023527542A5 (https=) | 2024-06-03 |
Family
ID=78722769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573247A Pending JP2023527542A (ja) | 2020-05-29 | 2021-05-27 | コレステロール関連障害を治療するためのｐｃｓｋ９阻害剤及びその使用の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230235085A1 (https=) |
| EP (1) | EP4157887A4 (https=) |
| JP (1) | JP2023527542A (https=) |
| CN (1) | CN115916838A (https=) |
| AR (1) | AR122180A1 (https=) |
| AU (1) | AU2021281256A1 (https=) |
| CA (1) | CA3179316A1 (https=) |
| IL (1) | IL298375A (https=) |
| JO (1) | JOP20220322A1 (https=) |
| TW (1) | TW202210524A (https=) |
| WO (1) | WO2021243002A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| CN121693519A (zh) | 2023-08-14 | 2026-03-17 | 信立泰(成都)生物技术有限公司 | Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法 |
| WO2025265012A1 (en) * | 2024-06-21 | 2025-12-26 | Amgen Inc. | Compositions comprising anti-pcsk9 antbodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009033743A1 (en) * | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| PL3169353T3 (pl) * | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
-
2021
- 2021-05-27 CA CA3179316A patent/CA3179316A1/en active Pending
- 2021-05-27 CN CN202180039317.4A patent/CN115916838A/zh active Pending
- 2021-05-27 AR ARP210101427A patent/AR122180A1/es unknown
- 2021-05-27 JP JP2022573247A patent/JP2023527542A/ja active Pending
- 2021-05-27 WO PCT/US2021/034489 patent/WO2021243002A1/en not_active Ceased
- 2021-05-27 IL IL298375A patent/IL298375A/en unknown
- 2021-05-27 EP EP21812361.0A patent/EP4157887A4/en active Pending
- 2021-05-27 US US17/999,373 patent/US20230235085A1/en active Pending
- 2021-05-27 AU AU2021281256A patent/AU2021281256A1/en active Pending
- 2021-05-28 TW TW110119435A patent/TW202210524A/zh unknown
-
2022
- 2022-11-27 JO JOJO/P/2022/0322A patent/JOP20220322A1/ar unknown